INMB
Income statement / Annual
Last year (2023), INmune Bio, Inc.'s total revenue was $155,000.00,
a decrease of 58.56% from the previous year.
In 2023, INmune Bio, Inc.'s net income was -$30.01 M.
See INmune Bio, Inc.�s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$155,000.00
|
$374,000.00
|
$181,000.00
|
$10,916.00
|
$77.69 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$155,000.00 |
$374,000.00 |
$181,000.00 |
$10,916.00 |
$77.69 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
1 |
1 |
1 |
1 |
1 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$20.27 M
|
$17.07 M
|
$20.54 M
|
$5.92 M
|
$3.28 M
|
$1.11 M
|
$435,362.00
|
$101,495.00
|
$0.00
|
| General & Administrative
Expenses |
$9.62 M
|
$9.26 M
|
$8.79 M
|
$6.32 M
|
$6.02 M
|
$11.33 M
|
$546,118.00
|
$125,996.00
|
$195,472.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$146,604.00
|
| Selling, General &
Administrative Expenses |
$9.62 M
|
$9.26 M
|
$8.79 M
|
$6.32 M
|
$6.02 M
|
$11.33 M
|
$546,118.00
|
$125,996.00
|
$48,868.00
|
| Other Expenses |
$0.00 |
-$1.35 M |
-$1.19 M |
$128,517.00 |
$0.00 |
$0.00 |
-$6.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$29.90 M |
$26.33 M |
$29.33 M |
$12.24 M |
$9.30 M |
$12.44 M |
$981,480.00 |
$227,491.00 |
$48,868.00 |
| Cost And Expenses |
$29.90 M |
$26.33 M |
$29.33 M |
$12.24 M |
$9.30 M |
$12.44 M |
$981,480.00 |
$227,491.00 |
$48,868.00 |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$77,688.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$1.35 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$29.74 M
|
$25.95 M
|
$29.15 M
|
$12.23 M
|
$9.30 M
|
$12.44 M
|
$981,480.00
|
$227,491.00
|
$195,472.00
|
| EBITDA |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$149,990.00
|
-$50,000.00
|
$146,604.00
|
| EBITDA Ratio |
0 |
-69.39 |
-161.07 |
-1120.16 |
-0.14 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-191.88
|
-69.39
|
-161.07
|
-1120.16
|
-0.1
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$267,000.00
|
-$1.35 M
|
-$1.19 M
|
$129,000.00
|
$77,688.00
|
$0.00
|
$149,994.00
|
-$50,000.00
|
$0.00
|
| Income Before Tax |
-$30.01 M |
-$27.30 M |
-$30.34 M |
-$12.10 M |
-$7.68 M |
-$12.44 M |
-$831,486.00 |
-$277,491.00 |
-$48,868.00 |
| Income Before Tax Ratio
|
-193.6
|
-72.99
|
-167.62
|
-1108.39
|
-0.1
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$1.35 M |
-$29.15 M |
-$12.23 M |
$1.46 M |
-$161,141.00 |
-$1.13 M |
-$177,491.00 |
$0.00 |
| Net Income |
-$30.01 M |
-$28.65 M |
-$30.34 M |
-$12.10 M |
-$9.14 M |
-$12.44 M |
-$831,486.00 |
-$277,491.00 |
-$48,868.00 |
| Net Income Ratio |
-193.6 |
-76.6 |
-167.62 |
-1108.39 |
-0.12 |
0 |
0 |
0 |
0 |
| EPS |
-1.67 |
-1.6 |
-1.88 |
-1.01 |
-0.89 |
-1.11 |
-0.0741 |
-0.0247 |
-0.0044 |
| EPS Diluted |
-1.67 |
-1.6 |
-1.88 |
-1.01 |
-0.89 |
-1.11 |
-0.0741 |
-0.0247 |
-0.0044 |
| Weighted Average Shares
Out |
$17.98 M
|
$17.93 M
|
$16.13 M
|
$11.99 M
|
$10.27 M
|
$11.22 M
|
$11.22 M
|
$11.22 M
|
$11.22 M
|
| Weighted Average Shares
Out Diluted |
$17.98 M
|
$17.93 M
|
$16.13 M
|
$11.99 M
|
$10.27 M
|
$11.22 M
|
$11.22 M
|
$11.22 M
|
$11.22 M
|
| Link |
|
|
|
|
|
|
|
|
|
